Viridos Technographics

Discover the latest software purchases and digital transformation initiatives being undertaken by Viridos and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 110 Viridos employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that Viridos has purchased the following applications: MetaViewer for AP Automation in 2024, easyMail Hosted IMAP for Application Hosting and Computing Services in 2018, Microsoft 365 for Collaboration in 2015 and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems Viridos is running and its propensity to invest more and deepen its relationship with MetaViewer , easyDNS , IBM or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing Viridos revenues, which have grown to $25.0 million in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Viridos intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.

Synthetic Genomics, Inc. (SGI) is a private biotechnology company harnessing the power of living cells — nature’s most efficient machines — to create transformative medicines and bio-based products. With our unmatched understanding of how DNA and RNA instruct the functions of life, we design biology for improved purpose and function. We have a track record of expanding the scientific horizon by delivering solutions that have never been possible. Our lead R&D programs focus on our self-amplifying RNA replicon platform for vaccines and therapeutics and novel "cell factories"​ for industr